Research & Education |
Clinical Trials |
Active Trials |
Phase 1
Phase 1
10A Multi-center, Placebo-controlled, randomized pilot study of the effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and Hepatocellular Carcinoma Treated with Ablative Therapy and/or Transarterial Chemoembolization
Disease/Condition: Hepatocellular Carcinoma
Principal Investigator: Guadalupe Garcia-Tsao |
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Tumor Malignancies
Disease/Condition: Advanced Solid Cancers
Principal Investigator: Howard S Hochster |
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Disease/Condition: Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
Principal Investigator: Scott Nicholas Gettinger |
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Breast Cancer (ER, PR, and HER2 negative) | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Melanoma | Non-Small Cell Lung Cancer (NSCLC) | Ovarian Cancer | Prostate Cancer
Principal Investigator: Roy Herbst |
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Disease/Condition: Malignant Melanoma
Principal Investigator: Mario Sznol |
